Please assess the completion status of the following clinical trial:

Trial Title: A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male and female adults with a diagnosis of PD and who were heterozygous carriers of a GBA mutation associated with PD.~* Participants carrying known sequence variants associated with GBA-PD must had rapid eye movement (REM) sleep behavior disorder (RBD) confirmed by historically documented polysomnography or by questionnaire.~* Age greater than or equal to (\>=) 18 years to 80 years inclusive at the time of informed consent signing (FOR JAPANESE PARTICIPANTS ONLY: Age \>=20 years to 80 years, inclusive, at the time of signing the informed consent. Note: Japanese participants refers only to Japanese participants enrolled and living in Japan).~* Had symptoms of PD \>=2 years.~* Hoehn and Yahr (H and Y) stage of 2 or lower at baseline.~* Stable medication regimen of PD drugs for at least 30 days (at least 60 days for rasagiline) prior to randomization.~* The participant was willing to abstain from grapefruit containing products for 72 hours prior to administration of the first dose of GZ/SAR402671 and for the duration of the entire treatment period (Part 1 and Part 2, Periods 2 and 3).~* Signed written consent.~Exclusion criteria:~* Parkinsonism due to drug(s) or toxin(s).~* Participants carrying the LRRK2 G2019S mutation.~* Participants with Gaucher disease (GD) as defined by clinical signs and symptoms (i.e., hepatosplenomegaly, cytopenia, skeletal disease) and/or marked deficiency of GCase activity compatible with GD.~* Montreal Cognitive Assessment score less than 20.~* Participants with prior surgical history of deep brain stimulation (DBS).~* Participants with baseline brain MRI without contrast showing a structural abnormality that is a possible cause of their PD signs or symptoms.~* Hepatic insufficiency with liver function tests (LFT) greater than (\>) 2 times upper limit of normal at Screening Visit.~* The participant had a documented diagnosis, as per local regulations, of any of the following infections: hepatitis B, hepatitis C, human immunodeficiency virus 1 or 2.~* Renal insufficiency as defined by creatine \>1.5 times normal at Screening Visit.~* The participant had received strong or moderate inducers or inhibitors of CYP3A4 within 30 days or 5 half-lives prior to randomization, whichever is longer.~* The participant had, according to World Health Organization (WHO) Grading, a cortical cataract \> one-quarter the lens circumference (grade cortical catact-2 \[COR-2\]) or a posterior subcapsular cataract \>2 millimeters (grade posterior subscapsular cataract \[PSC-2\]). Participant with nuclear cataracts would not be excluded.~* The participant was currently receiving potentially cataractogenic medications, including chronic regimen (more frequently than every 2 weeks) of any dose or route of corticosteroids or any medication that could cause cataract or worsen the vision of participants with cataract (eg, glaucoma medications) according to the Prescribing Information.~* If female, pregnant (defined as positive beta-human chorionic gonadotrophin \[Beta-HCG\] blood test) or lactating or breast-feeding.~* Any medical disorders and/or clinically relevant findings that, in the opinion of the Investigator, could interfere with study-related procedures. This included condition(s) that precluded the safe performance of routine lumbar punctures, such as prohibitive spinal diseases, bleeding diasthesis, or clinically significant coagulopathy or thrombocytopenia.~* Current participation in another investigational interventional study.~* Any medications specifically used for treating memory dysfunction, such as, but not limited to cholinesterase inhibitors or memantine, within 30 days or 5 half-lives of these medications prior to randomization, whichever was longer.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GZ/SAR402671 (Type: EXPERIMENTAL): Part 1: Increasing doses of GZ/SAR402671 were administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) was administered once per day.
- Placebo (Type: PLACEBO_COMPARATOR): A matching placebo for Parts 1 and 2 was administered once per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).